UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, ~~2021~~2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 001-39650

EUCRATES BIOMEDICAL ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

British Virgin Islands

001-39650

N/A

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification No.)

250 West 55^th Street, Suite 13D
New York, NY 10019

(Address of Principal Executive Offices, including zip code)

(212) 710-5220

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one ordinary share, no par value, and one-third of one Warrant	EUCRU	Nasdaq Capital Market
Ordinary shares, no par value	EUCR	Nasdaq Capital Market
Warrants, each whole warrant exercisable for one ordinary share at an exercise price of $11.50 per share	EUCRW	Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧☒ No ◻☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧☒ No ◻☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


◻☐ Large accelerated filer	◻☐ Accelerated filer
⌧☒ Non-accelerated filer	☒ Smaller reporting company
	☒ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☒ No ◻☐

As of August ~~16, 2021,~~15, 2022, there were 13,459,125 ordinary shares, no par value per share, issued and outstanding.

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORP.

FORM 10-Q FOR THE QUARTER ENDED JUNE 30, ~~2021~~2022

TABLE OF CONTENTS


			Page
Part I. Financial Information
	Item 1. Interim Financial Statements
		Condensed Balance Sheets as of June 30, ~~2021~~2022 (Unaudited) and December 31, ~~2020 (Audited)~~2021	1
		Condensed Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021 (Unaudited)	2
		Condensed ~~Statement~~Statements of Changes in Shareholders’ ~~Equity~~Deficit for the Three and Six Months Ended June 30, 2022 and 2021 (Unaudited)	3
		Condensed ~~Statement~~Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021 (Unaudited)	4
		Notes to Condensed Financial Statements (Unaudited)	5
	Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		1718
	Item 3. Quantitative and Qualitative Disclosures Regarding Market Risk		2022
	Item 4. Controls and Procedures		2022
Part II. Other Information
	Item 1. Legal Proceedings		2123
	Item 1A. Risk Factors		2123
	Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		2124
	Item 3. Defaults Upon Senior Securities		2225
	Item 4. Mine Safety Disclosures		2225
	Item 5. Other Information		2225
	Item 6. Exhibits		2225
Part III. Signatures			2326

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORP.

CONDENSED BALANCE SHEETS

June 30,

December 31,

2021

2020

(Unaudited)

(audited)
ASSETS

Current assets

Cash

$
383,231

$
551,264
Prepaid expenses

363,000

470,106
Total Current Assets

746,231

1,021,370

Marketable securities held in Trust Account

104,816,122

104,805,536
TOTAL ASSETS

$
105,562,353

$
105,826,906

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current liabilities - Accrued expenses

$
27,237

$
52,603
Warrant liability

3,759,993

6,623,910
Deferred underwriting fee payable

3,667,869

3,667,869
TOTAL LIABILITIES

7,455,099

10,344,382

Commitments and Contingencies

Ordinary shares subject to possible redemption 9,308,961 and 9,047,451 shares at redemption value as of June 30, 2021 and December 31, 2020, respectively

93,107,253

90,482,518

Shareholders’ Equity

Preferred shares, 0 par value; unlimited shares authorized; NaN issued and outstanding

0

0
Ordinary shares, 0 par value; unlimited shares authorized; 4,150,164 and 4,411,674 issued and outstanding (excluding 9,308,961 and 9,047,451 shares subject to possible redemption) as of June 30, 2021 and December 31, 2020, respectively

7,299,744

9,924,479
Accumulated deficit

(2,299,743)

(4,924,473)
Total Shareholders’ Equity

5,000,001

5,000,006
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

$
105,562,353

$
105,826,906


	June 30,		December 31,
	2022		2021
	(Unaudited)
ASSETS
Current assets
Cash	$	104,766	$	49,156
Prepaid expenses		117,402		215,000
Total Current Assets		222,168		264,156

Marketable securities held in Trust Account		104,954,769		104,842,820
TOTAL ASSETS	$	105,176,937	$	105,106,976

LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities:
Accrued expenses	$	14,986	$	38,460
Convertible promissory note - related party		186,900		—
Total current liabilities		201,886		38,460

Warrant liability		243,915		2,093,894
Deferred underwriting fee payable		3,667,869		3,667,869
TOTAL LIABILITIES		4,113,670		5,800,223

Commitments and Contingencies

Ordinary shares subject to possible redemption 10,479,626 shares at redemption value as of June 30, 2022 and December 31, 2021		104,854,768		104,796,260

Shareholders’ Deficit
Preferred shares, 0 par value; unlimited shares authorized; NaN issued and outstanding		—		—
Ordinary shares, 0 par value; unlimited shares authorized; 2,979,499 issued and outstanding (excluding 10,479,626 shares subject to possible redemption) as of June 30, 2022 and December 31, 2021		—		—
Accumulated deficit		(3,791,501)		(5,489,507)
Total Shareholders’ Deficit		(3,791,501)		(5,489,507)
TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT	$	105,176,937	$	105,106,976

The accompanying notes are an integral part of the unaudited condensed financial statements.

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORP.

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

Three Months

Six Months

Ended

Ended

June 30,

June 30,

2021

2021
Formation and operational costs

$
124,425

$
249,773
Loss from operations

(124,425)

(249,773)

Other income:

Interest earned on marketable securities held in Trust Account

7,226

20,905
Change in fair value of warrants

759,944

2,863,917
Unrealized loss on marketable securities held in Trust Account

(12,154)

(10,319)
Other income, net

755,016

2,874,503

Net income

$
630,591

$
2,624,730

Basic and diluted weighted average shares outstanding, Ordinary shares subject to possible redemption

9,245,479

9,147,012
Basic and diluted net income per share, Ordinary shares subject to possible redemption

$
0.00

$
0.00
Basic and diluted weighted average shares outstanding, Non-redeemable ordinary shares

4,213,646

4,312,113
Basic and diluted net income per share, Non-redeemable ordinary shares

$
0.15

$
0.61






	Three Months				Six Months
	Ended				Ended
	June 30,				June 30,
	2022		2021		2022		2021
Formation and operational costs	$	137,478	$	124,425	$	268,514	$	249,773
Loss from operations		(137,478)		(124,425)		(268,514)		(249,773)

Other income:
Interest earned on marketable securities held in Trust Account		136,425		7,226		189,595		20,905
Change in fair value of warrants		441,527		759,944		1,849,979		2,863,917
Change in fair value of convertible promissory note - related party		(1,200)		—		63,100		0
Unrealized loss on marketable securities held in Trust Account		(7,614)		(12,154)		(77,646)		(10,319)
Total other income, net		569,138		755,016		2,025,028		2,874,503

Net income	$	431,660	$	630,591	$	1,756,514	$	2,624,730

Basic and diluted weighted average shares outstanding, Redeemable ordinary shares		10,479,626		10,479,626		10,479,626		10,479,626
Basic and diluted net income per share, Redeemable ordinary shares	$	0.03	$	0.05	$	0.13	$	0.20

Basic and diluted weighted average shares outstanding, Non-redeemable ordinary shares		2,979,499		2,979,499		2,979,499		2,979,499
Basic and diluted net income per share, Non-redeemable ordinary shares	$	0.03	$	0.05	$	0.13	$	0.20

The accompanying notes are an integral part of the unaudited condensed financial statements.

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORP.

CONDENSED ~~STATEMENT~~STATEMENTS OF CHANGES IN SHAREHOLDERS’ ~~EQUITY~~DEFICIT

(UNAUDITED)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022

Total

Ordinary Shares

Accumulated

Shareholder’s


Shares

Amount

Deficit

Equity
Balance – January 1, 2021

4,411,674

$
9,924,479

$
(4,924,473)

$
5,000,006

Change in value of ordinary shares subject to redemption

(198,028)

(1,994,143)

—

(1,994,143)

Net income

—

—

1,994,139

1,994,139

Balance – March 31, 2021

4,213,646

$
7,930,336

$
(2,930,334)

$
5,000,002

Change in value of ordinary shares subject to redemption

(63,482)

(630,592)

—

(630,592)

Net income

0

0

630,591

630,591

Balance – June 30, 2021

4,150,164

$
7,299,744

$
(2,299,743)

$
5,000,001


						Total
	Ordinary Shares			Accumulated		Shareholders’
	Shares	Amount		Deficit		Deficit
Balance – January 1, 2022	2,979,499	$	0	$	(5,489,507)	$	(5,489,507)

Net income	—		—		1,324,854		1,324,854

Balance – March 31, 2022	2,979,499	$	—	$	(4,164,653)	$	(4,164,653)

Accretion of ordinary share subject to redemption	—		—		(58,508)		(58,508)

Net income	—		—		431,660		431,660

Balance – June 30, 2022	2,979,499	$	0	$	(3,791,501)	$	(3,791,501)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021


						Total
	Ordinary Shares			Accumulated		Shareholders’
	Shares	Amount		Deficit		Deficit
Balance – January 1, 2021	2,979,499	$	0	$	(9,313,736)	$	(9,313,736)

Net income	—		—		1,994,139		1,994,139

Balance – March 31, 2021	2,979,499	$	—	$	(7,319,597)	$	(7,319,597)

Net income	—		—		630,591		630,591

Balance – June 30, 2021	2,979,499	$	0	$	(6,689,006)	$	(6,689,006)

The accompanying notes are an integral part of the unaudited condensed financial statements.

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORP.

CONDENSED ~~STATEMENT~~STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months

Ended

June 30,

2021
Cash Flows from Operating Activities:

Net income

$
2,624,730
Adjustments to reconcile net income to net cash used in operating activities:

Change in fair value of warrant liability

(2,863,917)
Interest earned on marketable securities held in Trust Account

(20,905)
Unrealized loss on marketable securities held in Trust Account

10,319
Changes in operating assets and liabilities:

Prepaid expenses

107,106
Accrued expenses

(25,366)
Net cash used in operating activities

(168,033)

Net Change in Cash

(168,033)
Cash – Beginning

551,264
Cash – Ending

$
383,231

Non-Cash Investing and Financing Activities:

Change in value of ordinary share subject to possible redemption

$
2,624,735


	Six Months		Six Months
	Ended		Ended
	June 30,		June 30,
	2022		2021
Cash Flows from Operating Activities:
Net income	$	1,756,514	$	2,624,730
Adjustments to reconcile net income to net cash used in operating activities:
Change in fair value of warrant liability		(1,849,979)		(2,863,917)
Change in fair value of convertible promissory note - related party		(63,100)		—
Interest earned on marketable securities held in Trust Account		(189,595)		(20,905)
Unrealized loss on marketable securities held in Trust Account		77,646		10,319
Changes in operating assets and liabilities:
Prepaid expenses		97,598		107,106
Accrued expenses		(23,474)		(25,366)
Net cash used in operating activities		(194,390)		(168,033)

Cash Flows from Financing Activities:
Proceeds from promissory note - related party		250,000		—
Net cash provided by financing activities		250,000		—

Net Change in Cash		55,610		(168,033)
Cash – Beginning		49,156		551,264
Cash – Ending	$	104,766	$	383,231

Non-Cash Investing and Financing Activities:
Accretion for Ordinary Shares to redemption amount	$	58,508	$	7,944,263

The accompanying notes are an integral part of the unaudited condensed financial statements.

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, ~~2021~~2022

(Unaudited)

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

Eucrates Biomedical Acquisition Corporation (the “Company”) is a blank check company incorporated in the British Virgin Islands on August 21, 2020. The Company was formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with ~~one~~1 or more businesses or entities (“Business Combination”).

The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combinations. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

At June 30, ~~2021,~~2022, the Company had not yet commenced any operations. All activity from inception through June 30, ~~2021~~2022 relates to the Company’s formation and the initial public offering (“Initial Public Offering”), which is described ~~below.~~below and, subsequent to the Initial Public Offering, identifying a target company for a business combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company ~~will generate nonoperating~~generates non-operating income in the form of interest income from the proceeds derived from the ~~Initial Public Offering.~~marketable securities held in the Trust Account (as defined below).

The registration statement for the Company’s Initial Public Offering was declared effective on October 23, 2020. On October 27, 2020, the Company consummated the Initial Public Offering of 10,000,000 units (the “Units” and, with respect to the ordinary shares included in the Units sold, the “Public Shares”) at $10.00 per Unit, generating gross proceeds of $100,000,000.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 350,000 units (the “Private Units”) at a price of $10.00 per Private Unit in a private placement to the Company’s sponsor, Eucrates LLC (the “Sponsor”), generating gross proceeds of $3,500,000.

On November 20, 2020, the underwriters notified the Company of their intention to partially exercise their over-allotment option. As such, on November 24, 2020, the Company consummated the sale of an additional 479,626 Units, at $10.00 per Unit (see Note 3)4) and sold an additional 9,592 Private Units, at $10.00 per Private Unit (see Note 4)5), generating total gross proceeds of $4,892,185.

Transaction costs amounted to $6,168,976 consisting of $2,095,925 of underwriting fees, $3,667,869 of deferred underwriting fees and $405,182 of other offering costs.

Following the closing of the Initial Public Offering on October 27, 2020, ~~and~~ the partial exercise of the underwriters’ over-allotment exercise on November 24, 2020, and the sale of the Private Units, an aggregate amount of $104,796,260 ($10.00 per Unit) from the net proceeds of the sale of the Units was placed in a trust account (the “Trust Account”) located in the United States and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of ~~180~~185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the funds in the Trust Account to the Company’s shareholders, as described below.

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and sale of the Private Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the balance in the Trust Account (excluding the taxes payable on interest earned and less any interest earned thereon that is released for taxes) at the time of the signing of an agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination.

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, ~~2021~~2022

(Unaudited)

The Company will provide its shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek shareholder approval of a Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of whether they vote for or against the proposed Business Combination. The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 upon or immediately prior to such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination.

If the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from seeking redemption rights with respect to 15% or more of the Public Shares without the Company’s prior written consent.

The shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.00 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter (as discussed in Note 6). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.

If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, offer such redemption pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination.

The Sponsor has agreed (a) to vote its Founder Shares, the ordinary shares included in the Private Units (the “Private Shares”) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination, (b) not to propose an amendment to the Company’s Memorandum and Articles of Association with respect to the Company’s pre-Business Combination activities prior to the consummation of a Business Combination unless the Company provides dissenting public shareholders with the opportunity to redeem their Public Shares in conjunction with any such amendment; (c) not to redeem any shares (including the Founder Shares) into the right to receive cash from the Trust Account in connection with a shareholder vote to approve a Business Combination (or to sell any shares in a tender offer in connection with a Business Combination if the Company does not seek shareholder approval in connection therewith) or a vote to amend the provisions of the Memorandum and Articles of Association relating to shareholders’ rights of pre-Business Combination activity and (d) that the Founder Shares shall not participate in any liquidating distributions upon winding up if a Business Combination is not consummated. However, the Sponsor will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares purchased during or after the Initial Public Offering if the Company fails to complete its Business Combination.

The Company will have until October 27, 2022 to consummate a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than five business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (net of taxes payable), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the Company’s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirements of applicable law. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, ~~2021~~2022

(Unaudited)

The Sponsor has agreed that it will be liable to the Company, if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below $10.00 per share (whether or not the underwriters’ over-allotment option is exercised in full), except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company’s independent auditors), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

Liquidity and Going Concern

In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” the Company has until October 27, 2022 to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. The Company has $20,282 of working capital as of June 30, 2022 and may require additional capital to complete a Business Combination, which is available to the Company through the Promissory Note. Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after October 27, 2022.

Risks and Uncertainties

Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of the financial ~~statement.~~statements. The financial ~~statement does~~statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual ~~report~~Report on Form ~~10-K/A,~~10-K, as filed with the SEC on ~~July 15, 2021.~~April 11, 2022. The interim results for the three and six months ended June 30, ~~2021~~2022 are not necessarily indicative of the results to be expected for the year ending December 31, ~~2021~~2022 or for any future periods.

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

~~Table of Contents~~

~~EUCRATES BIOMEDICAL ACQUISITION CORPORATION~~

~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~

~~JUNE 30, 2021~~

~~(Unaudited)~~

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of ~~six~~three months or less when purchased to be cash equivalents. The Company did ~~not~~0t have any cash equivalents as of June 30, ~~2021~~2022 and December 31, ~~2020.~~2021.

Offering Costs

The Company complies with the requirement of Accounting Standard Codification (ASC) 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A – “Expenses of Offering”. Offering costs consisted of legal, accounting and other expenses incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to possible redemption upon the completion of the Initial Public Offering. Offering costs consist of legal, accounting and other expenses incurred through the balance ~~sheets~~sheet date that are directly related to the Initial Public Offering. Offering costs amounting to $6,057,930 were charged to ~~shareholders’~~temporary equity upon the completion of the Initial Public Offering and the partial exercise of the underwriters’ over-allotment and $111,046 of the offering costs were related to the warrant liabilities and charged to the statements of operations.

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

Marketable Securities Held in Trust Account

At June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, substantially all of the assets held in the Trust Account were held in money market funds, which primarily invest in U.S. Treasury securities. The Company accounts for its securities held in the trust account in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 320 “Debt and Equity Securities.” These securities are classified as trading securities with unrealized gains/losses, if any, recognized through the condensed statements of operations.

~~Table of Contents~~

~~EUCRATES BIOMEDICAL ACQUISITION CORPORATION~~

~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~

~~JUNE 30, 2021~~

~~(Unaudited)~~

Ordinary Shares Subject to Possible Redemption

The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in ~~Accounting Standards Codification (“ASC”)~~ASC Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as a component of shareholders’ equity. The Company’s ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders’ equity (deficit) section of the Company’s balance sheets. The redemption value of the ordinary shares subject to possible redemption as of June 30, 2022 is net of estimated dissolution expenses (see Note 1) of $100,000.

The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against ordinary shares and accumulated deficit.

At June 30, 2022 and December 31, 2021, the ordinary shares reflected in the condensed balance sheets are reconciled in the following table:


Gross proceeds	$	104,796,260
Less:
Proceeds allocated to Public Warrants		(1,886,333)
Ordinary shares issuance costs		(6,057,930)
Plus:
Accretion of carrying value to redemption value		7,944,263
Ordinary shares subject to possible redemption	$	104,796,260
Plus:
Accretion of carrying value to redemption value		58,508
Ordinary shares subject to possible redemption	$	104,854,768

Warrant ~~Liability~~Liabilities

The Company accounts for the Warrants in accordance with the guidance contained in ASC 815-40 under which the Warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company classifies the Warrants as liabilities at their fair value and adjust the Warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheets date until exercised, and any change in fair value is recognized in our statements of operations. The Private Placement Warrants and the Public Warrants for periods where no observable traded price was available are valued using a binomial lattice model. For periods subsequent to the detachment of the Public Warrants from the Units, the Public Warrant quoted market price was used as the fair value as of each relevant date.

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

Income Taxes

The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the British Virgin Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were 0 unrecognized tax benefits as of June 30, ~~2021~~2022 and December 31, ~~2020~~2021 and 0 amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

The Company may be subject to potential examination by foreign taxing authorities in the area of income taxes since inception. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with foreign tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

The Company is considered to be an exempted British Virgin Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the British Virgin Islands or the United States.

Net Income Per Share

The Company complies with accounting and disclosure requirements of Financial Accounting Standards Board (“FASB”) ASC Topic 260, “Earnings Per Share”. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of Class A ordinary shares is excluded from earnings per share as the redemption value approximates fair value.

The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants to purchase 359,592 Units is contingent upon the occurrence of future events. As of June 30, 2022 and 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods presented.

910

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, ~~2021~~2022

(Unaudited)

~~Net Income Per Share~~

Net income per share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the period, excluding ordinary shares subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 3,613,072 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.

The Company’s statements of operations includes a presentation of income per share for ordinary shares subject to possible redemption in a manner similar to the two-class method of income per share. Net income per ordinary share, basic and diluted, for Ordinary shares subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account by the weighted average number of Ordinary shares subject to possible redemption outstanding since original issuance.

Net income per share, basic and diluted, for non-redeemable ordinary shares is calculated by dividing the net income, adjusted for income or loss on marketable securities attributable to Ordinary shares subject to possible redemption, by the weighted average number of non-redeemable ordinary shares outstanding for the period.

Non-redeemable ordinary shares includes Founder Shares and non-redeemable ordinary shares as these shares do not have any redemption features. Non-redeemable ordinary shares participate in the income or loss on marketable securities based on non-redeemable shares’ proportionate interest.

The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts):

For the Three

For the Six

Months ended

Months ended

June 30,

June 30,


2021

2021
Ordinary shares subject to possible redemption


Numerator: Earnings allocable to Ordinary shares subject to possible redemption


Interest earned on marketable securities held in Trust Account

$
7,226

$
20,905
Unrealized loss on marketable securities held in Trust Account

(12,154)

(10,319)
Net income (loss) attributable to ordinary shares subject to possible redemption

$
(4,928)

$
10,586

Denominator: Weighted Average ordinary shares subject to possible redemption


Basic and diluted weighted average shares outstanding, ordinary shares subject to possible redemption

9,245,479

9,147,012
Basic and diluted net (loss) income per share, ordinary shares subject to possible redemption

$
0.00

$
0.00

Non-Redeemable Ordinary shares


Numerator: Net Income minus Net Earnings - Basic


Net Income

$
630,591

$
2,624,730
Less: Net loss allocable to ordinary shares subject to possible redemption

—

(9,404)
Non-Redeemable Net Income - Basic

$
630,591

$
2,615,326
Denominator: Weighted Average Non-Redeemable ordinary shares

Basic weighted average shares outstanding, Non-redeemable ordinary shares

4,213,646

4,312,113
Basic net income per share, Non-redeemable ordinary shares

$
0.15

$
0.61


	Three Months Ended								Six Months Ended
	June 30,��2022				June 30, 2021				June 30, 2022				June 30, 2021
	Redeemable		Non-redeemable		Redeemable		Non-redeemable		Redeemable		Non-redeemable		Redeemable		Non-redeemable
Basic and diluted net income per ordinary share
Numerator:
Allocation of net income, as adjusted	$	336,102	$	95,558	$	490,995	$	139,596	$	1,367,668	$	388,846	$	2,043,683	$	581,047
Denominator:
Basic and diluted weighted average ordinary share outstanding		10,479,626		2,979,499		10,479,626		2,979,499		10,479,626		2,979,499		10,479,626		2,979,499
Basic and diluted net income per ordinary share	$	0.03	$	0.03	$	0.05	$	0.05	$	0.13	$	0.13	$	0.20	$	0.20

~~As of June 30, 2021, basic and diluted shares are the same as there are no non-redeemable securities that are dilutive to the Company’s ordinary shareholders.~~

~~Table of Contents~~

~~EUCRATES BIOMEDICAL ACQUISITION CORPORATION~~

~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~

~~JUNE 30, 2021~~

~~(Unaudited)~~

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such accounts.

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature, excluding the Warrant Liability (see Note 9).

The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually.Fair Value Measurements

Level 1:

Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2:

Observable inputs other than Level 1 puts. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

Level 3:

Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

~~Fair Value Measurements~~

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, ~~2021~~2022

(Unaudited)

Convertible Promissory Note

The Company accounts for their convertible promissory note under ASC 815, “Derivatives and Hedging” (“ASC 815”). Under ASC 815-15-25, the election can be at the inception of a financial instrument to account for the instrument under the fair value option under ASC 825. The Company has made such election for their convertible promissory note. Using the fair value option, the convertible promissory note is required to be recorded at its initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the notes are recognized as a non-cash gain or loss on the condensed statements of operations.

Recent Accounting Standards

In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 must be adopted by January 1, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying condensed financial statements.

NOTE 3. INITIAL PUBLIC OFFERING

Pursuant to the Initial Public Offering and the underwriters’ partial exercise of their over-allotment option, the Company sold 10,479,626 Units, at a purchase price of $10.00 per Unit. Each Unit consists of 1 ordinary share and one-third of one redeemable warrant (“Public Warrant”). Each whole Public Warrant entitles the holder to purchase 1 ordinary share at an exercise price of $11.50 per share (see Note 7)8).

NOTE 4. PRIVATE PLACEMENT

Simultaneously with the closings of the Initial Public Offering and the underwriters’ partial exercise of their over-allotment option, the Sponsor purchased an aggregate of 359,592 Private Units at a price of $10.00 per Private Unit, or $3,595,925. The Private Units are identical to the Units sold in the Initial Public Offering, except for the private warrants (“Private Warrants”), as described in Note 8. If the Company does not complete a Business Combination within the Combination Period, the ~~proceeds from the sale of the Private Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the~~ Private Warrants will expire worthless.

NOTE 5. RELATED PARTY TRANSACTIONS

Founder Shares

In August 2020, the Sponsor paid $25,000 to cover certain offering costs of the Company in consideration for 2,875,000 of the Company’s ordinary shares (the “Founder Shares”). The Founder Shares included an aggregate of up to 375,000 shares subject to forfeiture by the Sponsor to the extent that the underwriters’ over-allotment was not exercised in full or in part, so that the Sponsor would collectively own 20% of the Company’s issued and outstanding shares after the Initial Public Offering (assuming the Sponsor did not purchase any Public Shares in the Initial Public Offering and excluding the Private Units and underlying securities). As a result of the underwriters’ election to partially exercise their over-allotment option on November 24, 2020, a total of 119,906 Founder Shares are no longer subject to forfeiture and 255,094 Founder Shares were forfeited, resulting in 2,619,906 Founder Shares issued and outstanding.

The Sponsor has agreed not to transfer, assign or sell any of the Founder Shares (except to certain permitted transferees) until the earlier of (A) one year after the completion of a Business Combination or (B) the date on which the closing price of the Company’s ordinary

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

shares equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing 150 days after a Business Combination, or earlier, in each case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the Company’s shareholders having the right to exchange their ordinary shares for cash, securities or other property.

~~Table of Contents~~

~~EUCRATES BIOMEDICAL ACQUISITION CORPORATION~~

~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~

~~JUNE 30, 2021~~

~~(Unaudited)~~

Related Party Loans

In order to finance transaction costs in connection with a Business Combination, the Company entered into a loan agreement with Eucrates LLC (the “Sponsor”) on January 20, 2022, that provides for borrowings of up to $600,000 (the “Promissory Note”). The Sponsor Loan is non-interest bearing and payable upon consummation of the Company’s initial Business Combination. On January 24, 2022, the Company made an initial draw on the Promissory Note of $250,000. At June 30, 2022, there was $250,000 of borrowings under the Sponsor Loan. This loan was valued using the fair value method. The fair value of the loan as of June 30, 2022, was $186,900, which resulted in a change in fair value of the convertible promissory note of ($1,200) and $63,100 recorded in the condensed statements of operations for the three and six months ended June 30, 2022 (see Note 9), respectively. The Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company additional funds as may be required ~~(“Working~~(together with the Sponsor Loan, the “Working Capital Loans”). ~~Such Working Capital Loans would be evidenced by promissory notes.~~ The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon consummation of a Business Combination into additional Private Units at a price of $10.00 per Unit. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The units would be identical to those units that were issued to the Sponsor in a private placement concurrent with the Company’s initial public offering. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. At June 30, 2022 and December 31, 2021, 0 such Working Capital Loans were outstanding.

NOTE 6. COMMITMENTS AND CONTINGENCIES

Registration Rights

Pursuant to a registration rights agreement entered into on October 23, 2020, the holders of the Founder Shares, Private Units (and their underlying securities) and any Units that may be issued upon conversion of the Working Capital Loans (and underlying securities) will be entitled to registration rights. The holders of 25% of these securities are entitled to make up to 3 demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The registration rights agreement does not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The underwriters are entitled to a deferred fee of $0.35 per Unit, or $3,667,869 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

NOTE 7. SHAREHOLDER’S ~~EQUITY~~DEFICIT

Preferred Shares — The Company is authorized to issue an unlimited number of ~~0 par~~0-par value preferred shares, divided into 5 classes, Class A through Class E, each with such designation, rights and preferences as may be determined by a resolution of the Company’s board of directors to amend the Memorandum and Articles of Association to create such designations, rights and preferences. The Company has 5 classes of preferred shares to give the Company flexibility as to the terms on which each Class is issued. All shares of a single class must be issued with the same rights and obligations. At June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, there are 0 preferred shares designated, issued or outstanding.

Ordinary Shares — The Company is authorized to issue an unlimited number of ~~0 par~~0-par value ordinary shares. Holders of the Company’s ordinary shares are entitled to one vote for each share. ~~As of~~At June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, there were ~~4,150,164 and 4,411,674~~2,979,499 shares of ordinary shares issued and outstanding,~~, which includes the 2,619,907 founder shares and excludes 9,308,961 and 9,047,451~~ excluding 10,479,626 ordinary shares subject to possible redemption ~~respectively.~~which are presented as temporary equity, respectively, so that the Sponsor will own 20% of the issued and outstanding shares after the Initial Public Offering (excluding the Private Units and assuming the Sponsor did not purchase any Units in the Initial Public Offering).

NOTE 8. WARRANTS

Warrants — Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a) 30 days after the consummation of a Business Combination or (b) 12 months from the effective date of the closing of the Initial Public Offering.

~~Table of Contents~~

~~EUCRATES BIOMEDICAL ACQUISITION CORPORATION~~

~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~

~~JUNE 30, 2021~~

~~(Unaudited)~~

The Company will not be obligated to deliver any ordinary shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those ordinary shares is available, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption from registration is available.

The Company has agreed that it will use its commercially reasonable efforts to file with the SEC and within 90 days following a Business Combination to have declared effective a registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and to maintain a current prospectus relating to those ordinary shares until the warrants expire or are redeemed. Notwithstanding the above, if the ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not ~~available~~available.

Redemption of warrants when the price per share of the ordinary shares equals or exceeds $18.00. Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described with respect to the Private Warrants):

●~~in whole and not in part;~~

●~~at a price of $0.01 per warrant;~~

●

in whole and not in part;

●

at a price of $0.01 per warrant;

●

upon a minimum of 30 days’ prior written notice of redemption, or the 30-day redemption period, to each warrant holder; and

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

●

if, and only if, the last reported sale price of the ordinary shares equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws.

Redemption of warrants when the price per share of the ordinary shares equals or exceeds $10.00. Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described with respect to the Private Warrants):

●

in whole and not in part;

●

at a price of $0.10 per warrant provided that holders will be able to exercise their warrants prior to redemption and receive that number of shares of ordinary shares based on the redemption date and the fair market value of the ordinary shares except as otherwise described below;

●

upon a minimum of 30 days’ prior written notice of redemption;

●

if, and only if, the last reported sale price of the ordinary shares equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders; and

~~Table of Contents~~

~~EUCRATES BIOMEDICAL ACQUISITION CORPORATION~~

~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~

~~JUNE 30, 2021~~

~~(Unaudited)~~

●

if, and only if, there is an effective registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and a current prospectus relating thereto available throughout the 30-day period after written notice of redemption is given.

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described above, the warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.

In addition, if (x) the Company issues additional shares or equity-linked securities for capital raising purposes in connection with the closing of an initial business combination at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors, and, in the case of any such issuance to the Sponsor or their affiliates, without taking into account any Founder Shares held by the Sponsor or their affiliates, as applicable, prior to such issuance) (the “newly issued price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a business combination on the date of the completion of a business combination (net of redemptions), and (z) the volume weighted average trading price of our shares during the 20 trading day period starting on the trading day prior to the day on which we complete our initial business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the newly issued price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the newly issued price.

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

The Private Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Warrants and the ordinary shares issuable upon the exercise of the Private Warrants will not be transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

NOTE 9. FAIR VALUE MEASUREMENTS

The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at June 30, ~~2021~~2022 and December 31, ~~2020~~2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:


	June 30, 2021						June 30,			December 31,
Description	Level	June 30, 2021		December 31, 2020		Level	2022		Level	2021
Assets:
Marketable securities held in Trust Account	1	$	104,816,122	$	104,805,536	1	$	104,954,769	1	$	104,842,820

Liabilities:
Warrant Liability – Public Warrants	1	$	3,632,937	$	6,392,572	1	$	235,821	1	$	2,024,156
Warrant Liability – Private Placement Warrants	3	$	127,056	$	231,338	3	$	8,094	3	$	69,738
Convertible Promissory Note - Related Party						3	$	186,900	3	$	—

~~Table of Contents~~

~~EUCRATES BIOMEDICAL ACQUISITION CORPORATION~~

~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~

~~JUNE 30, 2021~~

~~(Unaudited)~~

The valuation of Public warrants at December 31, 2020 were classified as Level 2 inputs as the warrants were not traded on a stand-alone basis until January, 2021. The December 31, 2020 value of the warrants was calculated as the difference between the closing quoted market price of the units less the closing quoted market price of the ordinary shares.

The Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on our accompanying June 30, 2022 and December 31, 2021 condensed balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the condensed statements of operations.

Level 3 financial liabilities consist of the Private Placement Warrant liability for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.

The fair value of the Private Placement Warrants was estimated at June 30, ~~2021~~2022 and December 31, ~~2020~~2021 to be ~~$1.06~~$0.07 and ~~$1.93,~~$0.58, respectively, using a binomial lattice option pricing model and the following assumptions:


	June 30,			December 31,			June 30,			December 31,
	2021			2020			2022			2021
Risk-free interest rate		0.81	%		0.39	%		2.98	%		1.19	%
Effective expiration date		3/12/2026			3/12/2026			11/20/2026			7/7/2026
Dividend yield		0.00	%		0.00	%		0.00	%		0.00	%
Expected volatility		17.8	%		26.1	%		1.7	%		12.1	%
Exercise price	$	11.5		$	11.50		$	11.50		$	11.50
Ordinary Share Price	$	9.85		$	10.05		$	9.90		$	9.76

Table of Contents

EUCRATES BIOMEDICAL ACQUISITION CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

The following table presents the changes in ~~the~~ fair value of the Level 3 warrant liabilities:

Private Placement

Public

Warrant Liabilities
Fair value as of December 31, 2020

$
231,338

$
6,392,572

$
6,623,910
Change in fair value of warrant

(77,912)

(2,026,061)

(2,103,973)
Fair value as of March 31, 2021

153,426

4,366,511

4,519,937
Change in fair value of warrant

(26,370)

(733,574)

(759,944)
Fair value as of June 30, 2021

$
127,056

$
3,632,937

$
3,759,993


					Level 3
	Private Placement		Public		Warrant Liabilities
Fair value as of December 31, 2021	$	69,738	$	0	$	69,738
Change in fair value of warrants		(46,982)		0		(46,982)
Fair value as of March 31, 2022	$	22,756	$	0	$	22,756
Change in fair value of warrants		(14,662)		0		(14,662)
Fair value as of June 30, 2022	$	8,094	$	0	$	8,094

There were 0 transfers in or out of Level 3 from other levels in the fair value hierarchy during the ~~three and~~ six months ended June 30, 2022 and 2021.

The fair value of the Convertible Promissory Note – Related Party was estimated at June 30, 2022 and January 24, 2022 (initial measurement) to be $186,200 and $186,900, respectively, using a discounted cash flow method and Black-Scholes model, which used the following assumptions:


	June 30,			January 24,
	2022			2022
Risk-free interest rate		2.98	%		2.42	%
Effective expiration date		11/20/2026			7/7/2026
Dividend yield		0.00	%		0.00	%
Expected volatility		1.7	%		4.8	%
Exercise price	$	11.50		$	11.50
Ordinary Share Price	$	9.90		$	9.84
Probability of transaction		75.0	%		75.0	%

The following table presents the changes in the fair value of the Level 3 Convertible Promissory Note – Related Party:


	Convertible
	Promissory
	Note
Fair value as of January 1, 2022	$	—
Proceeds received through convertible note - Related Party on January 24, 2022		250,000
Change in valuation inputs or other assumptions		(64,300)
Fair value as of March 31, 2022	$	185,700
Change in valuation inputs or other assumptions		1,200
Fair value as of June 30, 2022	$	186,900

NOTE 10. SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheets date up to the date that the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.

1617

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to Eucrates Biomedical Acquisition Corp. References to our “management” or our “management team” refer to our officers and directors, and references to the “Sponsor” refer to Eucrates LLC. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Special Note Regarding Forward-Looking Statements

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Exchange Act that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s Annual ~~report~~Report on Form ~~10-K/A~~10-K filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

This Management’s Discussion and Analysis of Financial Condition and Results of Operations has been amended and restated to give effect to the restatement of our financial statements as of June 30, 2021. Management identified errors made in its historical financial statements where, at the closing of our Initial Public Offering, we improperly valued our ordinary shares subject to possible redemption. We previously determined the ordinary shares subject to possible redemption to be equal to the redemption value of $10.00 per share of ordinary share while also taking into consideration a redemption cannot result in net tangible assets being less than $5,000,001. Management determined that the ordinary shares issued during the Initial Public Offering can be redeemed or become redeemable subject to the occurrence of future events considered outside of the Company’s control. Therefore, management concluded that the redemption value should include all ordinary shares subject to possible redemption, resulting in the ordinary shares subject to possible redemption being equal to their redemption value. As a result, management has noted a reclassification error related to temporary equity and permanent equity. This resulted in a restatement to the initial carrying value of the ordinary shares subject to possible redemption with the offset recorded to additional paid-in capital (to the extent available), accumulated deficit and ordinary shares.

Overview

We are a blank check company incorporated in the British Virgin Islands on August 21, 2020 formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar Business Combination with one or more businesses. We intend to effectuate our Business Combination using cash derived from the proceeds of the Initial Public Offering and the sale of the Private Units, our shares, debt or a combination of cash, shares and debt.

We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete a Business Combination will be successful.

Table of Contents

Results of Operations

We have neither engaged in any operations (other than searching for a Business Combination after our Initial Public Offering) nor generated any operating revenues to date. Our only activities from inception through June 30, ~~2021~~2022 were organizational activities, those necessary to prepare for the Initial Public Offering, described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination. We do not expect to generate any operating revenues until after the completion of our initial Business Combination. We expect to generate non-operating income in the form of interest income on marketable securities held after the Initial Public ~~Offering.~~Offering and changes in fair value of our warrants and promissory note. We expect that we will incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with searching for, and completing, a Business Combination.

For the three months ended June 30, 2022, we had net income of $431,660, which consisted of change in fair value of warrant liabilities of $441,527 and interest earned on marketable securities held in Trust Account of $136,425, offset by formation and operational costs of $137,478, change in fair value of convertible promissory note - related party of $1,200 and unrealized loss on marketable securities held in Trust Account of $7,614.

For the six months ended June 30, 2022, we had net income of $1,756,514, which consisted of change in fair value of warrant liabilities of $1,849,979, change in fair value of convertible promissory note - related party of $63,100 and interest earned on marketable securities held in Trust Account of $189,595, offset by formation and operational costs of $268,514 and unrealized loss on marketable securities held in Trust Account of $77,646.

For the three months ended June 30, 2021, we had a net income of $630,591, which consisted of change in fair value of ~~derivative liability~~warrant liabilities of $759,944, ~~and~~ interest earned on marketable securities held in Trust Account of $7,226, ~~offset by formation and operational costs of $124,425~~ and unrealized loss on marketable securities held in Trust Account of ~~$12,154.~~

~~Table~~$12,154, offset by formation and operational costs of ~~Contents~~$124,425.

For the six months ended June 30, 2021, we had a net income of $2,624,730 which consisted of change in fair value of ~~derivative liability~~warrant liabilities of $2,863,917 and interest earned on marketable securities held in Trust Account of $20,905, offset by formation and operational costs of $249,773 and unrealized loss on marketable securities held in Trust Account of $10,319.

Liquidity and Capital Resources

Until the consummation of the Initial Public Offering, our only source of liquidity was an initial purchase of ordinary shares by the Sponsor and loans from our Sponsor.

On October 27, 2020, we consummated the Initial Public Offering of 10,000,000 units at a price of $10.00 per Unit, generating gross proceeds of $100,000,000. Simultaneously with the closing of the Initial Public Offering, we consummated the sale of 350,000 Private Units to the Sponsor at a price of $10.00 per Private Unit generating gross proceeds of $3,500,000.

On November 24, 2020, the Company sold an additional 479,626 Units for total gross proceeds of $4,796,260 in connection with the underwriters’ partial exercise of their over-allotment option. Simultaneously with the partial closing of the over-allotment option, we also consummated the sale of an additional 9,592 Private Units at $10.00 per Private Unit, generating total proceeds of $95,925.

Following the Initial Public Offering, the partial exercise of the over-allotment option, and the sale of the Private Units, a total of $104,796,260 was placed in the Trust Account. We incurred $6,168,976 in transaction costs, including $2,095,925 of underwriting fees, $3,667,869 of deferred underwriting fees and $405,182 of other costs.

For the six months ended June 30, 2022, net cash used in operating activities was $194,390. Net income of $1,756,514 was impacted by interest earned on marketable securities held in Trust Account of $189,595, unrealized loss on marketable securities held in Trust Account of $77,646, change in fair value of warrant liabilities of $1,849,979 and change in fair value of convertible promissory note - related party of $63,100. Changes in operating assets and liabilities provided $74,124 of cash from operating activities.

Table of Contents

For the six months ended June 30, 2021, net cash used in operating activities was $168,033. Net income of $2,624,730 was impacted by interest earned on marketable securities held in Trust Account of $20,905, ~~and~~ change in fair value of ~~derivative liability~~warrant liabilities of $2,863,917, ~~offset by~~and unrealized loss on marketable securities held in Trust Account of $10,319. Changes in operating assets and liabilities provided $81,740 of cash from operating activities.

At June 30, ~~2021,~~2022, we had investments held in the Trust Account of ~~$104,816,122.~~$104,954,769. We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account, which interest shall be net of taxes payable and excluding deferred underwriting commissions, to complete our Business Combination. We may withdraw interest from the Trust Account to pay taxes, if any. To the extent that our share capital or debt is used, in whole or in part, as consideration to complete a Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

At June 30, ~~2021,~~2022, we held ~~$383,231~~$104,766 of cash outside of the Trust Account. We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, structure, negotiate and complete a Business Combination.

In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete a Business Combination, we may repay such loaned amounts out of the proceeds of the Trust Account released to us. In the event that a Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts, but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into additional Private Units, at a price of $10.00 per Unit, at the option of the lender.

On January 20, 2022, we issued an unsecured promissory note (the “Promissory Note”) to Eucrates LLC (the “Sponsor”). The Promissory Note provides that we may borrow up to an aggregate maximum amount of $600,000 from the Sponsor. On January 24, 2022, we made an initial draw on the Promissory Note of $250,000. Amounts up to the aggregate maximum amount may and are expected to be drawn down from time to time by us pursuant to the Promissory Note to fund its working capital requirements and for general corporate purposes. The Promissory Note does not bear any interest. If we complete an initial business combination, we would repay outstanding loaned amounts under the Promissory Note. In the event that we are unable to complete an initial business combination, we may use a portion of the working capital held outside its trust account to repay such loaned amounts but no proceeds from its trust account would be used for such repayment. The loans are convertible into units of the Company, at a price of $10.00 per unit, at the option of the Sponsor. The units would be identical to those units that were issued to the Sponsor in a private placement concurrent with our initial public offering.

Going Concern

We ~~do not believe~~have until October 27, 2022, to consummate a Business Combination. It is uncertain that we will ~~need~~be able to raise additional funds in order to meet the expenditures required for operating our business. However, if our estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiatingconsummate a Business Combination ~~are less than the actual amount necessary~~by this time. If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution. We have $20,282 of working capital as of June 30, 2022 and may require additional capital to ~~do so, we may have insufficient funds~~complete a Business Combination, which is available to ~~operate~~us through our ~~business prior to our initial Business Combination. Moreover, we may need to obtain additional financing either to complete our~~Promissory Note. Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or ~~because~~liabilities should we ~~become obligated~~be required to redeem a significant number of our public shares upon completion of our Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination.liquidate after October 27, 2022.

~~Table of Contents~~

Off-Balance Sheet Financing Arrangements

We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of June 30, ~~2021.~~2022. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Table of Contents

Contractual Obligations

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than described below.

The underwriter is entitled to a deferred fee of $0.35 per Unit, or $3,667,869 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the underwriting agreement.

Critical Accounting Policies

The preparation of condensed financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies.

Warrant ~~Liability~~Liabilities

We account for the Warrants in accordance with the guidance contained in ASC 815-40 under which the Warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the Warrants as liabilities at their fair value and adjust the Warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance ~~sheets~~sheet date until exercised, and any change in fair value is recognized in our statements of operations. The Private Placement Warrants and the Public Warrants for periods where no observable traded price was available are valued using a binomial lattice model. For periods subsequent to the detachment of the Public Warrants from the Units, the Public Warrant quoted market price was used as the fair value as of each relevant date, except for ~~12/31/20~~December 31, 2020 when the Public Warrants price was derived as the difference between the price of the Units and the price of the ordinary shares due to a lack of quoted prices for the public warrants.

Ordinary Shares Subject to Possible Redemption

We account for our ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) isare classified as temporary equity. At all other times, ordinary shares are classified as a component of shareholders’ equity. Our ordinary shares feature certain redemption rights that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders’ equity (deficit) section of our balance sheets.

Net Income per Ordinary Share

Net income per ordinary share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value.

1921

Table of Contents

~~Net Income (Loss) per Ordinary Share~~

We apply the two-class method in calculating earnings per share. Net income (loss) per ordinary share, basic and diluted for ordinary shares subject to possible redemption is calculated by dividing the interest income earned on the Trust Account, net of applicable taxes, if any, by the weighted average number of shares of ordinary shares subject to possible redemption outstanding for the period. Net income (loss) per ordinary share, basic and diluted for non-redeemable ordinary share is calculated by dividing net loss less income attributable to ordinary shares subject to possible redemption, by the weighted average number of shares of non-redeemable ordinary shares outstanding for the period presented.

Recent Accounting Standards

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our condensed financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure controls ~~and procedures~~ are ~~controls and other~~ procedures that are designed ~~to ensure~~with the objective of ensuring that information required to be disclosed in our reports filed ~~or submitted~~ under the Exchange Act is recorded, processed, summarized, and reported within the time ~~periods~~period specified in the SEC’s rules and forms. Disclosure controls ~~and procedures include, without limitation, controls and procedures~~are also designed ~~to ensure~~with the objective of ensuring that such information ~~required to be disclosed in our reports filed or submitted under the Exchange Act~~ is accumulated and communicated to our management, including the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer ~~to allow timely decisions regarding required disclosure.~~

~~Evaluation of Disclosure Controls and Procedures~~

~~Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted~~carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of ~~the end of the fiscal quarter ended~~ June 30, ~~2021, as such term is~~2022. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange ~~Act. Based on this evaluation, our principal executive officer and principal financial and accounting officer have concluded that,~~Act) were not effective, due solely ~~due~~ to the events that led to the Company’s restatement of its financial statements to reclassify the Company’s derivative instruments as liabilities (which are described in the Company’s Amendment No. 1 to its Annual Report on Form 10-K/A filed on July 15, 2021) (the “Restatement”), during the period covered by this report, a material weakness ~~existed and our disclosure controls and procedures were not effective.~~

~~Changes in Internal Control Over Financial Reporting~~

~~There were no changes~~ in our internal control over financial reporting ~~(as defined~~related to the Company’s accounting for complex financial instruments. As a result, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in ~~Rules 13a-15(f)~~accordance with GAAP. Accordingly, management believes that the financial statements included in this Quarterly Report present fairly in all material respects our financial position, results of operations and ~~15d-15(f) under~~cash flows for the Exchange Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. In light of theperiods presented.

Management has identified a material weakness ~~identified and~~in internal controls related to the ~~resulting Restatement,~~accounting for complex financial instruments. While we ~~plan to enhance our~~have processes to identify and appropriately apply applicable accounting requirements, we plan to ~~better evaluate~~continue to enhance our system of evaluating and ~~understand~~implementing the ~~nuances of the complex~~ accounting standards that apply to our financial ~~statements. Our plans at this time include providing~~statements, including through enhanced ~~access to accounting literature, research materials and documents and increased communication among~~analyses by our personnel and third-party professionals with whom we consult regarding complex accounting applications. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

2022

Table of Contents

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

None.

ITEM 1A. RISK FACTORS.

Factors that could cause our actual results to differ materially from those in this Quarterly Report include the risk factors described in our Annual Report on Form ~~10-K/A~~10-K filed with the SEC on ~~July 15, 2021.~~April 11, 2022. As of the date of this Quarterly Report, other than as described below, there have been no material changes to the risk factors disclosed in our ~~final prospectus~~Annual Report on Form 10-K filed with the SEC.

The securities in which we invest the funds held in the Trust Account could bear a negative rate of interest, which could reduce the value of the assets held in trust such that the per-share redemption amount received by public shareholders may be less than $10.00 per share.

The proceeds held in the Trust Account are invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act, which invest only in direct U.S. government treasury obligations. While short-term U.S. government treasury obligations currently yield a positive rate of interest, they have briefly yielded negative interest rates in recent years. Central banks in Europe and Japan pursued interest rates below zero in recent years, and the Open Market Committee of the Federal Reserve has not ruled out the possibility that it may in the future adopt similar policies in the United States. In the event that we are unable to complete our initial business combination or make certain amendments to our Amended and Restated Memorandum and Articles of Association our public shareholders are entitled to receive their pro-rata share of the proceeds held in the Trust Account, plus any interest income not released to us, net of taxes payable. Negative interest rates could impact the per-share redemption amount that may be received by public shareholders.

Our business, our search for a business combination, and any target business with which we ultimately consummate a business combination may be negatively impacted as a result of Russian actions in Ukraine.

In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine that is still continuing. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. The impact of this action and related sanctions on the world economy are not determinable as of the date of this Quarterly Report and the specific impact on the company’s financial condition, results of operations, and cash flows is also not determinable as of the date of this Quarterly Report. These actions and related sanctions could adversely affect economies and financial markets worldwide, business operations and the conduct of commerce generally, and the business of any potential target business with which we consummate a business combination could be, or may already have been, materially and adversely affected. The extent to which these actions and related sanctions impact our search for and ability to consummate a business combination will depend on future developments, which are highly uncertain and cannot be predicted.

The number of special purpose acquisition companies (“SPACs”) evaluating targets has increased and attractive targets may become scarcer and there may be more competition for attractive targets. This could increase the cost of our initial business combination and could even result in our inability to find a target or to consummate an initial business combination.

In recent years, the number of SPACs that have been formed has increased substantially. Many potential targets for SPACs have already entered into an initial business combination, and there are still many SPACs seeking targets preparing for their initial business combination public offering, as well as many such companies currently in registration with the Securities and Exchange Commission. As a result, at times, fewer attractive targets may be available, and it may require more time, more effort and more resources to identify a suitable target and to consummate an initial business combination.

Table of Contents

In addition, because there are more SPACs seeking to enter into an initial business combination with available targets, the competition for available targets with attractive fundamentals or business models may increase, which could cause targets companies to demand improved financial terms. Attractive deals could also become scarcer for other reasons, such as economic or industry sector downturns, geopolitical tensions, or increases in the cost of additional capital needed to close business combinations or operate targets post-business combination. This could increase the cost of, delay or otherwise complicate or frustrate our ability to find and consummate an initial business combination and may result in our inability to consummate an initial business combination on terms favorable to our investors altogether.

Cyber incidents or attacks directed at us could result in information theft, data corruption, operational disruption and/or financial loss.

We depend on digital technologies, including information systems, infrastructure and cloud applications and services, including those of third parties with which we may deal. Sophisticated and deliberate attacks on, or security breaches in, our systems or infrastructure, or the systems or infrastructure of third parties or the cloud, could lead to corruption or misappropriation of our assets, proprietary information and sensitive or confidential data. As an early stage company without significant investments in data security protection, we may not be sufficiently protected against such occurrences. We may not have sufficient resources to adequately protect against, or to investigate and remediate any vulnerability to, cyber incidents. It is possible that any of these occurrences, or a combination of them, could have adverse consequences on our business and lead to financial loss.

Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete our initial business combination, and results of operations.

We are subject to laws and regulations enacted by national, regional and local governments. In particular, we are required to comply with certain SEC and other legal requirements. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. Those laws and regulations and their interpretation and application may also change from time to time and those changes could have a material adverse effect on our business, investments and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business, including our ability to negotiate and complete our initial business combination, and results of operations.

On March 30, 2022, the SEC issued proposed rules relating to, among other items, enhancing disclosures in business combination transactions involving special purpose acquisition companies and private operating companies; amending the financial statement requirements applicable to transactions involving shell companies; the potential liability of certain participants in proposed business combination transactions; and the extent to which special purpose acquisition companies could become subject to regulation under the Investment Company Act of 1940, as amended. These rules, if adopted, whether in the form proposed or in revised form, may materially adversely affect our ability to negotiate and complete our initial business combination and may increase the costs and time related thereto.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

On October 27, 2020, we consummated our Initial Public Offering of 10,000,000 Units. On November 24, 2020, in connection with the underwriters’ election to partially exercise their over-allotment option, we sold an additional 479,626 Units. The Units sold in the Initial Public Offering and the partial exercise of over-allotment option sold at an offering price of $10.00 per Unit, generating total gross proceeds of $104,796,260. Stifel, Nicolaus & Company, Incorporated and H.C. Wainwright & Co., LLC acted as joint book-running managers. The securities sold in the offering were registered under the Securities Act on registration statements on Form S-1 (No. 333-24333). The registration statements became effective on October 23, 2020.

Simultaneously with the consummation of the Initial Public Offering, and the partial exercise of the over-allotment option, we consummated a private placement of 359,592 Private Units to our Sponsor at a price of $10.00 per Private Unit, generating total proceeds of $3,595,925. Such securities were issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

The Private Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Warrants are not transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions.

Table of Contents

Of the gross proceeds received from the Initial Public Offering including the over-allotment option, and the sale of the Private Units, $104,796,260 was placed in the Trust Account.

We paid a total of $2,095,925 in underwriting discounts and commissions and $405,182 for other costs and expenses related to the Initial Public Offering. In addition, the underwriter agreed to defer $3,667,869 in underwriting discounts and commissions.

For a description of the use of the proceeds generated in our Initial Public Offering, see Part I, Item 2 of this Form 10-Q.

~~Table of Contents~~

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.


No.		Description of Exhibit
31.1*		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certification of Principal Executive Officer Pursuant and Principal Financial Officer to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		XBRL Instance Document
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH*		XBRL Taxonomy Extension Schema Document
101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

*~~Filed herewith.~~

**Furnished.

*	Filed herewith.

**	Furnished.

2225

Table of Contents

SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	EUCRATES BIOMEDICAL ACQUISITION CORP.

Date: August ~~16, 2021~~15, 2022		/s/ Parag Saxena
	Name:	Parag Saxena
	Title:	Chief Executive Officer
		(Principal Executive Officer)

Date: August ~~16, 2021~~15, 2022		/s/ Gonzalo Cordova
	Name:	Gonzalo Cordova
	Title:	Chief Financial Officer
		(Principal Financial and Accounting Officer)

2326


	For the Three		For the Six
	Months ended		Months ended
	June 30,		June 30,
	2021		2021
Ordinary shares subject to possible redemption
Numerator: Earnings allocable to Ordinary shares subject to possible redemption
Interest earned on marketable securities held in Trust Account	$	7,226	$	20,905
Unrealized loss on marketable securities held in Trust Account		(12,154)		(10,319)
Net income (loss) attributable to ordinary shares subject to possible redemption	$	(4,928)	$	10,586

Denominator: Weighted Average ordinary shares subject to possible redemption
Basic and diluted weighted average shares outstanding, ordinary shares subject to possible redemption		9,245,479		9,147,012
Basic and diluted net (loss) income per share, ordinary shares subject to possible redemption	$	0.00	$	0.00

Non-Redeemable Ordinary shares
Numerator: Net Income minus Net Earnings - Basic
Net Income	$	630,591	$	2,624,730
Less: Net loss allocable to ordinary shares subject to possible redemption		—		(9,404)
Non-Redeemable Net Income - Basic	$	630,591	$	2,615,326
Denominator: Weighted Average Non-Redeemable ordinary shares
Basic weighted average shares outstanding, Non-redeemable ordinary shares		4,213,646		4,312,113
Basic net income per share, Non-redeemable ordinary shares	$	0.15	$	0.61